Indication
HER2-negative Metastatic Breast Cancer
4 clinical trials
7 products
Clinical trial
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast CancerStatus: Completed, Estimated PCD: 2023-09-13
Product
NiraparibProduct
DAN-222Clinical trial
Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 StudyStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management. The MINERVA Trial - A Phase IV TrialStatus: Recruiting, Estimated PCD: 2029-04-01
Product
Abemaciclib + FulvestrantClinical trial
DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor CellsStatus: Completed, Estimated PCD: 2022-01-01
Product
Lapatinib